Multi-arm Study to Support the Ability to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR Study)
The purpose of this clinical trial is to evaluate the efficacy of I+V and ibrutinib monotherapy regimens using a tailored treatment approach in which dosing of ibrutinib is either proactively reduced or reactively modified (per the label) in response to AEs, compared with clinical trial-based historical controls of ibrutinib monotherapy and I+V.
Chronic Lymphocytic Leukemia
Megha Shah, MD
If you have any questions regarding this study or think that you or your loved one may be eligible, please contact our Clinical Trial Coordinator by dialing 908.237.1201 extension 262.
Sign up for the HHO newsletter to stay up to date on the latest news within the practice and the community.